CG Oncology Starts Phase 3 Trial of Cretostimogene in Bladder Cancer

  PIVOT-006 Phase 3 open-label trial of adjuvant cretostimogene is CG Oncology’s earliest disease stage clinical trial for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) -

- Primary endpoint of PIVOT-006 Phase 3 clinical trial is overall recurrence-free survival (RFS), with secondary endpoints including RFS at 12 and 24 months and progression-free survival (PFS) -

https://www.biospace.com/article/releases/cg-oncology-announces-first-patient-dosed-in-pivot-006-phase-3-clinical-trial-of-cretostimogene-in-intermediate-risk-non-muscle-invasive-bladder-cancer/